When Hormone Therapy Is Not the Whole Answer for Low Libido: What Else to Look At

Start with the map. If you have not yet worked out which layers are in play for you, read our main guide first: Low Libido in Women: Why It Is Multifactorial and How to Address It. It covers the whole system — hormones, brain chemistry, comfort, mood, sleep, medications and relationship — and how to sort which is driving yours. This page is the next step: what to do when the hormone layer has been addressed and desire still has not returned.

The short version. Before adding anything, subtract: the modifiable factors — medication effects, pain, sleep, mood, thyroid and iron — are addressed first, because they are common, they are fixable, and nothing layered on top works well until they are. After that there are centrally acting options, regenerative options and psychosexual therapy, each with a different weight of evidence behind it. We say which is which.

First, Subtract

The international process-of-care algorithm for low desire in women is explicit about sequence: a biopsychosocial assessment of potentially modifiable factors comes first, then treatment begins with education and modification of those factors, and only then, if needed, does additional therapeutic intervention follow — sex therapy, centrally acting agents, or hormonal therapy guided in part by menopausal status (Clayton et al., Mayo Clin Proc, 2018, DOI).

That order matters practically. Adding a second medication on top of an unaddressed cause is how people end up on four things and no better.

When Pain or Dryness Is the Actual Barrier

This is the single most common reason a hormone protocol appears not to work. If sex is uncomfortable, desire does not survive it — and the anticipation of discomfort suppresses interest long before anything happens.

Genitourinary syndrome of menopause affects more than half of women through the transition, and it is one of the more treatable problems in this whole field. Low-dose vaginal estrogen improves symptom severity by approximately 60 to 80 percent, vaginal prasterone by 40 to 80 percent, and oral ospemifene by 30 to 50 percent (Crandall et al., JAMA, 2023, DOI). Local therapy is low-dose and works on tissue where it is applied, which is a different proposition from systemic hormone therapy.

Pain that does not fit that picture — a specific site, pain on entry versus deep pain, pain with a clear onset — needs its own examination rather than being folded into a desire conversation. Pelvic floor muscle dysfunction, vestibular pain and dermatologic conditions of the vulva all present as "low libido" until someone looks.

Medications That Suppress Desire

Worth reviewing line by line before anything is added:

• SSRIs and SNRIs. The most common culprit we see. Options include a dose adjustment, a switch to an antidepressant with fewer sexual side effects, adding an adjunct, or strengthening therapy so medication can be reduced. Because psychiatric mental health is one of the three certifications here, that adjustment happens in-house rather than as a referral.
• Combined oral contraceptives, particularly older formulations, which raise SHBG and lower the free hormone fraction available to tissue. The effect can persist for a while after stopping.
• Certain blood pressure medications, including some beta blockers and older agents.
• Antihistamines and anticholinergics, which reduce lubrication.
• Alcohol, in more than modest amounts, which fragments sleep and blunts arousal even when it feels like it does the opposite.

Never stop a prescribed medication on the strength of a web page. Bring the list to a visit and it gets reviewed properly.

Sleep, Thyroid, Iron and Prolactin

These are the four that most often explain a hormone protocol that did not deliver.

Sleep sits upstream of everything, and obstructive sleep apnea is meaningfully underdiagnosed in women, whose presentation is often fatigue and low mood rather than loud snoring. Fragmented sleep suppresses desire directly and through every other route.

Thyroid disease imitates hormone decline almost perfectly. A TSH alone is the usual screen and it misses conversion and antibody issues that a fuller picture would show.

Iron deficiency, with or without anemia, is common in perimenopause because bleeding is often heavy, and it produces exactly the exhaustion that ends interest. Ferritin is the marker.

Prolactin, when elevated, flattens desire and changes the whole plan. It is a cheap test and it is worth doing.

How each of these markers is drawn, timed and interpreted is set out in our guide to hormone lab testing and monitoring.

When Testosterone Is the Right Tool — and When It Is Not

Testosterone has real evidence behind it for the right patient. The Global Consensus Position Statement, endorsed by eleven international societies, supports low, female-dose testosterone for postmenopausal women with distressing low desire (Davis et al., J Clin Endocrinol Metab, 2019, DOI), and a systematic review in The Journal of Sexual Medicine found the strongest evidence in postmenopausal women, where randomized trials showed robust benefits for sexual desire with transdermal testosterone (DOI: 10.1093/jsxmed/qdag206).

Two honest qualifications. First, the clinical practice guideline recommends systemic transdermal testosterone for women whose low desire is not primarily related to modifiable factors or comorbidities such as relationship or mental health problems — which is precisely why the subtraction step comes first — and describes the therapeutic benefit as moderate (Parish et al., J Sex Med, 2021, DOI). Second, a total testosterone level should not be used to diagnose low desire; it is a baseline for monitoring, kept within the physiologic premenopausal range (Parish et al., 2021, DOI). A normal number does not rule the diagnosis out, and a low one does not rule it in.

If you have had a well-monitored trial at proper dose for six to twelve weeks and nothing changed, that is useful information. It usually means the driver is elsewhere.

Centrally Acting Options

Bremelanotide (PT-141)

Bremelanotide is FDA-approved for premenopausal women with hypoactive sexual desire disorder. It acts on melanocortin receptors in the brain rather than on hormones or blood flow, and it is given as an as-needed subcutaneous injection.

The evidence is two identical phase 3 randomized, double-blind, placebo-controlled trials known as RECONNECT, in which 1,267 premenopausal women with HSDD were randomized to bremelanotide 1.75 mg or placebo for 24 weeks. Both trials showed statistically significant increases in sexual desire and significant reductions in distress related to low desire compared with placebo, with a favorable safety profile; the most common side effects were nausea, flushing and headache, mostly mild or moderate (Kingsberg et al., Obstet Gynecol, 2019, DOI). The responder definitions used in those trials were developed and validated beforehand in a phase 2b dose-ranging study (Althof et al., J Sex Med, 2019, DOI).

Read the effect sizes rather than the headline: these were real, statistically significant improvements, and they were moderate rather than transformative. That is a reasonable thing to want, and it is worth knowing in advance.

Kisspeptin

Kisspeptin is a genuinely interesting research direction and should be described as exactly that. In a randomized, double-masked, placebo-controlled crossover trial, 32 premenopausal women with HSDD received kisspeptin-54 infusion or placebo. Kisspeptin modulated sexual and facial-attraction brain processing on functional imaging, and its effects on hippocampal and posterior cingulate activity correlated with baseline sexual distress and with reduced sexual aversion. It was well tolerated with no reported adverse effects, and the authors framed the findings as laying foundations for future clinical applications (Thurston et al., JAMA Netw Open, 2022, DOI).

That is a brain-imaging study in 32 women, not an approved treatment with outcome data. We mention it because patients ask, and because the direction is promising — not because it is ready to be a plan.

Regenerative Options: PRP and the O-Shot

Platelet-rich plasma is prepared from your own blood and injected into the anterior vaginal wall and surrounding tissue, with the aim of supporting tissue quality, blood flow and sensitivity.

Here is the evidence as it stands. A systematic review of PRP for female sexual dysfunction and stress urinary incontinence found that across the included studies PRP significantly improved the Female Sexual Function Index, the Vaginal Health Index and the Female Sexual Distress Score, with a typical protocol of 2 mL injected into the distal anterior vaginal wall once a month for three months. The same authors are direct that the level of current evidence is low because of methodological limitations in the available studies, and that higher-quality research is needed (Dankova et al., Biomedicines, 2023, DOI). A separate randomized comparison in postmenopausal women with vulvovaginal atrophy found both PRP and hyaluronic acid injection effective, with hyaluronic acid showing the greater improvement on sexual function scores and no complications in either group (Ragy et al., Arch Dermatol Res, 2025, DOI).

Our position: PRP is a reasonable option to discuss, particularly alongside local therapy for tissue quality, and it should be chosen with the actual state of the evidence in front of you rather than a promise. Arbour Longevity offers it as part of the sexual wellness programme.

Therapy, and Why It Is Not the Consolation Prize

Sex therapy is one of the named treatment arms in the international process of care, alongside centrally acting agents and hormonal therapy — behavior therapy, cognitive behavior therapy and mindfulness (Clayton et al., 2018, DOI). It is not what you are offered when the medical options run out.

For many women desire is responsive rather than spontaneous: it arrives after arousal begins, once the conditions are right. When that is the pattern, the useful intervention is often about conditions, attention and context rather than about a molecule. Depression, anxiety, past trauma and long-running stress all belong here too, and they are treatable.

Putting It Together

A workable sequence, roughly:

1. Review every medication, and address the ones that suppress desire.
2. Treat pain and dryness directly, because nothing else works while sex is uncomfortable.
3. Fix sleep, and screen properly for apnea if the picture fits.
4. Check thyroid fully, plus ferritin and prolactin.
5. Treat mood and stress as part of the plan rather than after it.
6. Then, and only then, consider adding: testosterone where it is indicated, a centrally acting option, a regenerative option, therapy, or a combination.

Most women need two or three of these, not one. That is the honest shape of it.

Frequently Asked Questions

I tried testosterone and nothing happened. What now?

A well-monitored trial at proper dose that produced nothing after six to twelve weeks is genuinely useful information: it points away from the hormone layer. The next step is a careful review of medications, pain, sleep, thyroid, ferritin, prolactin and mood, which is where the answer usually is.

Is bremelanotide the same thing as testosterone?

No. It works on melanocortin receptors in the brain rather than through hormones, it is taken as needed rather than continuously, and it is FDA-approved for premenopausal women with HSDD on the strength of two phase 3 randomized trials (Kingsberg et al., 2019, DOI).

Does the O-Shot work?

Studies to date report improvements in Female Sexual Function Index, Vaginal Health Index and distress scores, and the authors of the systematic review are equally clear that the evidence base is small and methodologically limited (Dankova et al., 2023, DOI). It is a reasonable option to consider with that framing, not a guaranteed result.

Do I have to stop my antidepressant?

No. A dose adjustment, a switch to an agent with fewer sexual side effects, or an adjunct are all options, and mood is managed alongside desire rather than traded against it.

Could this just be my relationship?

Sometimes, partly, and it is asked about directly rather than assumed. Biologically driven low desire also occurs in strong relationships, and it can strain them in ways that look like the relationship is the cause. Sorting that out is the point of a proper assessment. The full picture is in our main guide to low libido in women.

How long before I know whether something is working?

Sleep and lifestyle changes shift things over 2 to 8 weeks. Local vaginal estrogen takes 4 to 8 weeks. Testosterone takes 6 to 12 weeks for full effect. Bremelanotide acts within roughly 45 minutes to 2 hours per dose. PRP effects develop over several weeks. We set the review date at the start rather than waiting to see.

Talk to Someone About It

Nothing on this page is medical advice for you specifically, and none of it needs to be decided alone. The first visit is $35, applied toward your treatment plan, and it is a full evaluation with a recommendation on which labs and next steps make sense — not a product pitch.

Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC is a triple board certified nurse practitioner and founder of Arbour Longevity, 2217 Packard St #15, in the Eastover Professional Center, Ann Arbor, MI 48104. Open Thursday through Monday, 10am to 7pm, closed Tuesday and Wednesday. Parking is free and directly outside — no meters, no structure. Suite 15 is down a flight of stairs; if stairs are difficult for you, please call (734) 436-3357 before your visit.

Call (734) 436-3357 or book a confidential first visit. Cash pay, HSA and FSA accepted.

References

According to PubMed, the clinical evidence cited on this page includes:

1. Clayton AH, Goldstein I, Kim NN, et al. The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. Mayo Clin Proc. 2018;93(4):467-487. PMID: 29545008. DOI: 10.1016/j.mayocp.2017.11.002
2. Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023;329(5):405-420. PMID: 36749328. DOI: 10.1001/jama.2022.24140
3. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID: 31498871. DOI: 10.1210/jc.2019-01603
4. Parish SJ, Simon JA, Davis SR, et al. ISSWSH Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867. PMID: 33814355. DOI: 10.1016/j.jsxm.2020.10.009
5. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840. DOI: 10.1097/AOG.0000000000003500
6. Althof S, Derogatis LR, Greenberg S, et al. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019;16(8):1226-1235. PMID: 31277966. DOI: 10.1016/j.jsxm.2019.05.012
7. Thurston L, Hunjan T, Ertl N, et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(10):e2236131. PMID: 36287566. DOI: 10.1001/jamanetworkopen.2022.36131
8. Dankova I, Pyrgidis N, Tishukov M, et al. Efficacy and Safety of Platelet-Rich Plasma Injections for the Treatment of Female Sexual Dysfunction and Stress Urinary Incontinence: A Systematic Review. Biomedicines. 2023;11(11):2919. PMID: 38001920. DOI: 10.3390/biomedicines11112919
9. Ragy S, Kahky HE, Elfakkar NMZ, et al. Injection of hyaluronic acid versus platelet rich plasma for treatment of vulvovaginal atrophy in post-menopausal females. Arch Dermatol Res. 2025;317(1):305. PMID: 39853463. DOI: 10.1007/s00403-025-03820-z
10. Furlan VA, Hammad MAM, Quesada S, et al. Testosterone therapy for female sexual dysfunction: a systematic review. J Sex Med. 2026;23(8). DOI: 10.1093/jsxmed/qdag206
11. Heald A, Illangasekera Y, Rehman H, et al. Changes in serum testosterone concentration following application of testosterone gel in post-menopausal women with HSDD. Clin Endocrinol (Oxf). 2026;105(1):77-84. DOI: 10.1111/cen.70119
12. Ashour AM. Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women. Front Med (Lausanne). 2026;13:1789809. DOI: 10.3389/fmed.2026.1789809

Clinical information here is drawn from articles retrieved from PubMed and provided for education. It is not medical advice, a diagnosis, or a promise of any result.